A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Epistemonikos ID: 0caae1aa129c46ab41ebd7357624a771e980f9c9
First added on: May 15, 2024